Sanquin Plasma Products B.V. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Amsterdam Netherlands

Primary Industry

Biotechnology

About

Founded in 2015 and based in Amsterdam, Netherlands, Sanquin Plasma Products B.V., also known as SPP, engages in the production and exportation of medicines derived from blood plasma. In December 2020, a consortium led by Fortissimo Capital, along with Biosolutions, LLC, EpsteinCap, OBF Investments, and Mesola Inversiones, acquired a majority stake in the company from Sanquin Blood Supply Foundation. As part of the transaction, Mr. Chris Lamb, the founder of BioSolutions LLC, will be appointed as the CEO of SPP. The company offers plasma medicinal products. SPP uses biotechnological methods to compose pharmaceuticals from blood plasma and offer contract manufacturing and tech transfer services to pharmaceutical companies.

Current Investors

Fortissimo Capital, EpsteinCap, Biosolutions, LLC

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceuticals

Website

www.plasmaproducts.com

Verticals

Manufacturing

Company Stage

Mature - Buyout

Total Amount Raised

Subscriber access only

Deals

Deals Type
Buyout

Deal Status	Target (s)	Deal Date	Investor(s)	Seller(s)	Deal size (Mn)	Enterprise value (Mn)	Post-money valuation (Mn)	EBITDA multiple (x)	Revenue multiple (x)	Lead partner (s)
Completed	Sanquin Plasma Products B.V.	12 Oct 2020

Displaying 1-1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.